Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3179.00    95.00 (3.08%)
Bid:
3186.00
Ask:
3188.00
Spread: 2.00 (0.063%)
Market Cap: £4.43b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Acquisition

24 May 2013 07:00

RNS Number : 4809F
Croda International PLC
24 May 2013
 



24 May 2013

 

Croda International Plc

 

Acquisition ofSpecialty Products Business from Arizona Chemical

Naturally derived polyamides expand Croda's broad portfolio of effects

 

Croda International Plc announces today that it has completed the acquisition of the Specialty Products business of Arizona Chemical based in Jacksonville, Florida in the USA. 

 

The acquisition adds a portfolio of class leading oil gelling polymers to Croda's business and further expands its footprint in the polymers arena, while strengthening Croda's leading position in speciality chemicals derived from renewable resources. The technologies and products of the acquired business are naturally derived polyamides with high bio-renewable content, covered by a range of patents.

 

Keith Layden, Croda's Chief Technology Officer, said:

 

"This acquisition represents further progress in our strategy to acquire complementary new technologies. The varied functionality of these specialised polyamides will be a valuable addition to our offerings across both the Consumer Care and Performance Technologies market sectors. In addition, there are a number of opportunities to further differentiate the technology and create value for ourselves and our customers."

 

No manufacturing assets will be acquired as part of this transaction and Croda will immediately commence the relocation of the products to Croda's Mevisa manufacturing site in Spain and when ready, re-launch the products with new trade names and marketing identities.

 

For further information please contact:

 

Keith Layden, Chief Technology Officer Tel: 01405 860 551

Sean Christie, Group Finance Director

 

Charles Armitstead / Rosie Oddy, Pendomer Communications Tel: 020 3603 5224 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQAJMATMBJTBFJ
Date   Source Headline
26th Apr 20198:21 amRNSTotal Voting Rights
25th Apr 201910:25 amRNSDirectorate Change
25th Apr 20199:53 amRNSResult of AGM
12th Apr 20194:28 pmRNSDirector/PDMR Shareholding
8th Apr 20194:45 pmRNSDirector/PDMR Shareholding
4th Apr 20199:32 amRNSDirector/PDMR Shareholding
2nd Apr 20199:04 amRNSDirector/PDMR Shareholding
28th Mar 201911:13 amRNSDirector/PDMR Shareholding
26th Mar 20198:16 amRNSDirector/PDMR Shareholding
18th Mar 20195:26 pmRNSAnnual Financial Report
13th Mar 20191:42 pmRNSDirector/PDMR Shareholding
12th Mar 20192:22 pmRNSDirector/PDMR Shareholding
12th Mar 20192:21 pmRNSDirector/PDMR Shareholding
11th Mar 20192:16 pmRNSDirector/PDMR Shareholding
6th Mar 20193:53 pmRNSTransaction in Own Shares
6th Mar 201910:07 amRNSDirector/PDMR Shareholding
6th Mar 201910:07 amRNSDirector/PDMR Shareholding
6th Mar 201910:06 amRNSDirector/PDMR Shareholding
6th Mar 201910:03 amRNSDirector/PDMR Shareholding
6th Mar 201910:02 amRNSDirector/PDMR Shareholding
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:00 amRNSDirector/PDMR Shareholding
6th Mar 20199:58 amRNSDirector/PDMR Shareholding
6th Mar 20199:57 amRNSDirector/PDMR Shareholding
26th Feb 20197:00 amRNSResults for the year ended 31 December 2018
12th Feb 20194:47 pmRNSDirector/PDMR Shareholding
11th Jan 20194:21 pmRNSDirector/PDMR Shareholding
31st Dec 20187:00 amRNSAcquisition completion
17th Dec 20187:00 amRNSAcquisition of global vaccine adjuvant specialist
12th Dec 20181:14 pmRNSDirector/PDMR Shareholding
22nd Nov 20181:54 pmRNSDirector Declaration
22nd Nov 20188:07 amRNSDirector/PDMR Shareholding
14th Nov 20182:48 pmRNSDirector/PDMR Shareholding
14th Nov 20188:24 amRNSDirector/PDMR Shareholding
1st Nov 20187:00 amRNSTrading Update for the Third Quarter 2018
26th Oct 20187:00 amRNSAcquisition update
12th Oct 20181:42 pmRNSDirector/PDMR Shareholding
4th Oct 20183:03 pmRNSDirector/PDMR Shareholding
4th Oct 20183:01 pmRNSDirector/PDMR Shareholding
28th Sep 20183:35 pmRNSDirector/PDMR Shareholding
11th Sep 20184:50 pmRNSDirector/PDMR Shareholding
6th Sep 20184:07 pmRNSDirector/PDMR Shareholding
5th Sep 20187:00 amRNSAppointment of Broker
22nd Aug 201811:06 amRNSDirector Declaration
13th Aug 20184:37 pmRNSDirector/PDMR Shareholding
7th Aug 20189:11 amRNSDirector/PDMR Shareholding
31st Jul 20184:16 pmRNSDirector/PDMR Shareholding
25th Jul 20184:19 pmRNSDirector/PDMR Shareholding
25th Jul 20187:00 amRNSResults for the six months ended 30 June 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.